Join
Live feed
·
PRReleasevia Quantisnow
Merck & Company Inc. logo
NeOnc Technologies Holdings Inc. logo

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

ByQuantisnow·Wall Street's wire, on your screen.
MRK· Merck & Company Inc.NTHI· NeOnc Technologies Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MRK (Merck & Company Inc.), NTHI (NeOnc Technologies Holdings Inc.) and more on Quantisnow.

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET | Quantisnow